| Enbrel (etanercept) / Pfizer, Amgen |
NCT00195377: Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain |
|
|
| Completed | N/A | 1000 | Europe | Etanercept | Wyeth is now a wholly owned subsidiary of Pfizer | Arthritis, Psoriatic, Arthritis, Rheumatoid | 04/06 | 04/06 | | |
| Completed | N/A | 600 | US | Enbrel® | Amgen, Immunex Corporation | Juvenile Rheumatoid Arthritis | 01/08 | 01/08 | | |
NCT00195403: A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA |
|
|
| Completed | N/A | 1014 | RoW | Etanercept | Pfizer | Rheumatoid Arthritis | 02/08 | 02/08 | | |
NCT00116727: Rheumatoid Arthritis DMARD Intervention and UtilizationStudy |
|
|
| Completed | N/A | 5103 | US | ENBREL® | Amgen, Immunex Corporation, Wyeth is now a wholly owned subsidiary of Pfizer | Rheumatoid Arthritis | 06/08 | 10/08 | | |
|
NCT00195364: Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain |
|
|
| Completed | N/A | 93 | Europe | Etanercept | Wyeth is now a wholly owned subsidiary of Pfizer | Rheumatoid Arthritis, Inflammation | 10/08 | 10/08 | | |
NCT00724672: A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521) |
|
|
| Withdrawn | N/A | 0 | Europe | etanercept, Enbrel®, infliximab, Remicade®, SCH 215596, adalimumab, Humira® | Merck Sharp & Dohme LLC | Rheumatoid Arthritis | 07/09 | 07/09 | | |
NCT00273858: Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis |
|
|
| Terminated | N/A | 880 | Europe | There is no Intervention. The study is observational. | Wyeth is now a wholly owned subsidiary of Pfizer | Ankylosing Spondylitis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Spondylitis, Ankylosing | 07/10 | 07/10 | | |
FALLA, NCT01083160: Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use |
|
|
| Terminated | N/A | 82 | RoW | | Abbott | Rheumatoid Arthritis | 11/10 | 11/10 | | |
NCT00195338: Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg |
|
|
| Completed | N/A | 25 | Europe | etanercept | Pfizer, Innovex, Inc | Rheumatoid Arthritis | 12/10 | 12/10 | | |
MAINTAIN, NCT01692899: Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice |
|
|
| Completed | N/A | 780 | Europe | | Pfizer, scientific steering committee of KOL in rheumatology | Rheumatoid Arthritis | 09/11 | 09/11 | | |
RACAT, NCT00405275: Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy |
|
|
| Completed | N/A | 353 | US, Canada | Etanercept, Enbrel, methotrexate, Sulfasalazine, Hydroxychloroquine, Plaquenil, Placebo, triple, Placebo, etanercept | US Department of Veterans Affairs, Canadian Institutes of Health Research (CIHR), Rheumatoid Arthritis Investigational Network (RAIN), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Rheumatoid Arthritis | 12/11 | 05/12 | | |
|
NCT00888576: Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan |
|
|
| Completed | N/A | 441 | RoW | | Pfizer | Rheumatoid Arthritis | 12/11 | 12/11 | | |
NCT01646385: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry |
|
|
| Completed | N/A | 6393 | Europe | etanercept, non-biologic anti-rheumatic drugs | Pfizer | Rheumatoid Arthritis | 08/12 | 08/12 | | |
NCT01557322: Characterize Patients With Moderately Active Rheumatoid Arthritis (RA) |
|
|
| Completed | N/A | 1754 | US | etanercept, Enrel, methotrexate (MTX), non-biologic DMARD | Pfizer | Rheumatoid Arthritis | 09/12 | 09/12 | | |
NCT01388608: Standard Disease Activity Parameters and Step Activity in Patients With Rheumatoid Arthritis Receiving Etanercept |
|
|
| Completed | N/A | 28 | Europe | | University Hospital Muenster | Rheumatoid Arthritis | 01/13 | 04/13 | | |
| Terminated | N/A | 160 | RoW | Enbrel, etanercept | Pfizer | Rheumatoid Arthritis, Ankylosing Spondylitis | 01/13 | 01/13 | | |
| Completed | N/A | 4945 | Europe | etanercept, Enbrel | Pfizer | Rheumatoid Arthritis | 04/13 | 04/13 | | |
NCT00503139: Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan |
|
|
| Completed | N/A | 684 | Japan | Enbrel (etanercept) | Pfizer | Rheumatoid Arthritis | 04/13 | 04/13 | | |
| Completed | N/A | 113 | Japan | Etanercept (genetical recombination), Enbrel | Pfizer | Juvenile Idiopathic Arthritis | 10/13 | 10/13 | | |
NCT00116272: Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project |
|
|
| Completed | N/A | 830 | US | Etanercept, Enbrel | Amgen | Pregnancy | 06/14 | 06/14 | | |
ANTIBODY-RA, NCT01981473: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab |
|
|
| Completed | N/A | 605 | US, Europe, RoW | no intervention, Enbrel, Humira, Remicade | Pfizer | Rheumatoid Arthritis | 12/14 | 12/14 | | |
NCT01558089: Good EULAR Response In Patients With Early Rheumatoid Arthritis |
|
|
| Completed | N/A | 76 | Europe | etanercept, methotrexate | Pfizer | Rheumatoid Arthritis | 05/15 | 05/15 | | |
NCT01877239: Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria |
|
|
| Completed | N/A | 111 | Europe | non-intervention | Pfizer | Rheumatoid Arthritis | 01/16 | 06/16 | | |
| Completed | N/A | 126 | Europe | Blood test | Assistance Publique - Hôpitaux de Paris | Juvenile Idiopathic Arthritis | 02/17 | 03/17 | | |
REACH RA, NCT02202837: Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice |
|
|
| Completed | N/A | 157 | Europe | etanercept | Pfizer | Rheumatoid Arthritis | 04/17 | 04/17 | | |
